The public is giving the cold shoulder to the South Korean bio companies and their recent investments. A number of bio companies have apparently invested in Optimus fund that caused loss of about 500 billion won from an alleged fraud. And as the public found out about the fraud, the bio companies could not avoid their harsh reproach.

Once valued at 5 trillion won, Helixmith came under fire from the investors as it was uncovered to have invested a large sum of over 200 billion won.

This is not to criticize a private company investing on a high-risk hedge fund. Like any other individual investors, companies can carry out diverse investment models to multiply their assets. However, the pr